Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.

Translated title of the contribution: Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.

C.J. van der Woude, P. Stokkers, A.A. van Bodegraven, G. van Assche, Z. Hebzda, L. Paradowski, G. D'Haens, S. Ghosh, B. Feagan, P. Rutgeerts, G. Dijkstra, D.J. de Jong, B. Oldenburg, M. Farhan, T. Richard, Y. Dean, D.W. Hommes

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPhase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
Original languageUndefined/Unknown
Pages (from-to)1708-1716
Number of pages9
JournalInflammatory bowel diseases
Volume16
Issue number10
Publication statusPublished - 2010

Cite this